What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
Por:
Aapro, M, Barnadas, A, Leonard, RC, Marangolo, M, Untch, M, Ukarma, L, Burger, HU, Scherhag, A, Osterwalder, B
Publicada:
1 nov 2009
Resumen:
Purpose, patients and methods: This retrospective analysis of the BRAVE study evaluated the impact of baseline risk factors and antithrombotic therapy on the risk of thrombovascular events (TVEs) in patients receiving epoetin compared to patients not receiving epoetin. Results: Baseline risk factors have a significant impact on TVE risk under epoetin therapy. More than 2 risk factors increased the risk of TVEs in patients receiving epoetin (hazard ratio [HR] 2.89, confidence interval [CI] 1.04-8.02, p value [p] = 0.04). In patients on epoetin without antithrombotic therapy, the risk for TVEs was higher (HR 4.11, CI 1.37-12.4, p = 0.01) compared to those who received antithrombotics (HR 1.37, CI 0.59-3.18, p = 0.45). Conclusions: Our analysis has identified several risk factors which may impact the risk of TVEs under epoetin therapy. These data suggest that antithrombotic therapy may have the potential to reduce the risk of TVEs under epoetin therapy. These findings are hypothesis-generating and need to be confirmed in a prospective, randomised study. (C) 2009 Elsevier Ltd. All rights reserved.
Filiaciones:
Aapro, M:
Clin Genolier, Inst Multidisciplinaire Oncol, CH-1272 Genolier, Switzerland
Barnadas, A:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Leonard, RC:
Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Canc Serv & Clin Haematol, London, England
Marangolo, M:
Osped Prov Sta Maria delle Croci, Div Oncol, Ravenna, Italy
Untch, M:
HELIOS Klin, Berlin, Germany
Ukarma, L:
Hoffmann La Roche Ltd, Basel, Switzerland
Burger, HU:
Hoffmann La Roche Ltd, Basel, Switzerland
Scherhag, A:
Hoffmann La Roche Ltd, Basel, Switzerland
Heidelberg Univ, Med Clin 1, Univ Hosp Mannheim, D-6900 Heidelberg, Germany
Osterwalder, B:
Hoffmann La Roche Ltd, Basel, Switzerland
|